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2-O-sulfotransferaseHeparan sulfate (HS) is a complex and highly variable polysaccharide, expressed ubiquitously on the cell surface
as HS proteoglycans (HSPGs), and found in the extracellularmatrix as free HS fragments. Its heterogeneity due to
various acetylation and sulfation patterns endows amultitude of functions. In animal tissues, HS interacts with a
wide range of proteins to mediate numerous biological activities; given its multiple roles in inflammation
processes, characterization of HS in human serum has significant potential for elucidating disease mechanisms.
Historically, investigation of HS was limited by its low concentration in human serum, together with the
complexity of the serum matrix. In this study, we used a modified mass spectrometry method to examine HS
disaccharide profiles in the serum of 50 women with rheumatoid arthritis (RA), and compared our results to
51 sera from healthy women. Using various purification methods and online LC–MS/MS, we discovered
statistically significant differences in the sulfation and acetylation patterns between populations. Since early
diagnosis of RA is considered important in decelerating the disease's progression, identification of specific
biomolecule characterizations may provide crucial information towards developing new therapies for suppress-
ing the disease in its early stages. This is the first report of potential glycosaminoglycan biomarkers for RA found
in human sera, while acknowledging the obvious fact that a larger population set, and more stringent collection
parameters, will need to be investigated in the future.
© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Rheumatoid arthritis (RA) is a common autoimmune disease of
unknown cause, associated with painfully stiff, swollen joints, bone
and cartilage destruction, cardiovascular complications, progressive dis-
ability and early death (Aletaha et al., 2010; McInnes and Schett, 2011).
RA is characterized by synovial inflammation and autoantibody produc-
tion (rheumatoid factor and anti-citrullinated protein antibody [ACPA])
(McInnes and Schett, 2011). It is believed that heparan sulfate partici-
pates in the persistent inflammation of RA through its involvement in
leukocyte transmigration, the essential feature of the inflammatory
response (Parish, 2006). Heparan sulfate appears to be involved not
only in the transmigration of leukocytes to underlying target tissue, it
also plays a role in the recruitment of leukocytes from the blood, and
in the activation of certain chemokines (Santiago et al., 2012; Ferro,
2013).Davis, One Shields Avenue,
ll 130, Davis, CA 95616, USA.
pen access article under the CC BY-NHeparin/heparan sulfate (HS) is a member of the glycosaminoglycan
(GAG) family of polysaccharides (Rabenstein, 2002). It is a negatively
charged linear polysaccharide, consisting of 50–200 repeating disaccha-
ride units, formed of hexuronic acids (L-iduronic or D-glucuronic) which
are α(1 → 4) linked to glucosamine units, with various sulfation
and acetylation patterns (Table 1) (Saad and Leary, 2003; Zaia and
Costello, 2003; Wei et al., 2013). Proteoglycans are proteins to which
glycosaminoglycans are covalently attached; heparan sulfate proteogly-
cans (HSPGs) have heparan sulfate covalently attached as their carbohy-
drate component (Parish, 2006). HS constitutes the most structurally
complex member of the GAG family (Rabenstein, 2002), and both
HSPG and free HS are ubiquitously expressed on the cell surface and in
the extracellular matrix (Parish, 2006; Wei et al., 2011; Ferro, 2013).
The heterogeneous structures of HS are created through a non-
template-driven biosynthetic pathwaywith the cooperation of several
enzymes. The biosynthesis is initiated from a backbone composed
of alternating GlcNAc and GlcUA residues. The N-deacetylase/N-
sulfotransferase (NDST) enzymes replace N-acetates with N-sulfates,
producing NS (N-sulfated domain), NA (unmodified contiguous N-
acetylated domain) and NS/NA (transitional domain with alternative
N-acetates and N-sulfates) domains (Kreuger et al., 2002; Staples
et al., 2010; Sheng et al., 2011). Some of the GlcUA residues are replaced
with IdoUA by C-5 epimerase enzymes. Further modifications involveC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Structures of 12 heparin/heparan sulfate-derived disaccharides.
Disaccharide R2 R6 Y
ΔUA2S → GlcNAc6S SO3 SO3 COCH3
ΔUA → GlcNAc6S H SO3 COCH3
ΔUA2S → GlcNAc SO3 H COCH3
ΔUA → GlcNAc H H COCH3
ΔUA2S → GlcNS6S SO3 SO3 SO3
ΔUA → GlcNS6S H SO3 SO3
ΔUA2S → GlcNS SO3 H SO3
ΔUA → GlcNS H H SO3
ΔUA2S → GlcN6S SO3 SO3 H
ΔUA → GlcN6S H SO3 H
ΔUA2S → GlcN SO3 H H
ΔUA → GlcN H H H
55J.K. Sabol et al. / Matrix Biology 40 (2014) 54–61the introduction of 2-O-sulfates, 6-O-sulfates and more rarely, 3-O-
sulfates by 2-O-sulfotransferase (2OST), 6-O-sulfotransferases (6OSTs)
and 3-O-sulfotransferases (3OSTs), respectively (Liu et al., 1999;
Perrimon and Bernfield, 2000; Staples et al., 2010). Heparan sulfate
can also be modified by editing enzymes, such as 6-O-endo-sulfatases
and heparanase (Ai et al., 2003; Ilan et al., 2006; Xu et al., 2007). The
extracellular 6-O-endo-sulfatases, Sulf1 and Sulf2, selectively remove
sulfate groups from the carbon 6 positions (Lamanna et al., 2008;
Rosen and Lemjabbar-Alaoui, 2010; Nagamine et al., 2012), while
heparanase cleaves HS chains from the protein core, generating free
HS (Bernfield et al., 1999; Galvis et al., 2007).
In animal tissues, HS interacts with a wide range of functionally
diverse proteins (such as growth factors, cytokines, chemokines, prote-
ases, and cell-adhesionmolecules) (Parish, 2006) tomediate numerous
biological activities, including many stages of the inflammatory process
(Ferro, 2013). Such interactions are significantly affected by variable
sulfation and acetylation sequences (Bernfield et al., 1999; Perrimon
and Bernfield, 2000). Through specific modification of the HS chains
expressed, cells can direct their interactions with HS-binding proteins
(Parish, 2006). The structural diversity of HS endows a multitude of
functions and explains its contribution to a variety of disease states.
Given the considerable involvement of HS in inflammation processes,
characterization of HS and HSPG in serum has significant potential
for elucidating disease mechanisms. Since early diagnosis of RA is
considered important in decelerating the disease's progression, identifi-
cation of biomolecule characterizations specific to RA may provide cru-
cial information towards developing new therapies for suppressing RA
in its early stages.
In this study, we performed compositional analysis of HS/HSPG
from human serum samples, and discovered statistically significant
differences in the sulfation and acetylation patterns between popula-
tions. According to compositional analysis methodology previously re-
ported by this group (Wei et al., 2011, 2013), HS disaccharide profiles
of 50 serum samples from women diagnosed with RA were analyzed
using various chromatographic methods and online LC–MS/MS. This is
the first report of potential glycosaminoglycan biomarkers found in
human RA sera.2. Results
Analytical separation and mass spectrometry methodology were
used for the analysis of 50 rheumatoid arthritis (RA) serum samples,
from pre- and post-menopausal women. Sera were purified using
weak anion exchange chromatography, in which the eluted fraction
contained both HS and HSPG, and subsequently separated using50 kDa MWCO filters. Both HS (flow through) and HSPG (retained on
filters) fractions were enzymatically digested into disaccharides,
purified by SPE and analyzed by LC–MS/MS (Wei et al., 2011, 2013).
Commercially available heparan sulfate from bovine kidney, human
serum from Sigma, and a pooled sample of 50 RA sera (Freue et al.,
2013) were used as control samples for daily precision and accuracy.
The data from these samples were compared and analyzed statistically.
The differences between healthy and RA disaccharide profiles were
observed and discussed below.2.1. Increased amounts of HS and HSPG in RA sera
Increased amounts of HS and HSPG were observed in the RA sample
population compared to the healthy sample population, irrespective of
menopausal status. The total HS and HSPG amounts were calculated
using a modified version of a method previously published by this
group (Wei et al., 2013). The median amount of free HS (μg/ml) was
1.7 times greater in the RA samples than in the healthy samples. Similar-
ly, themedian amount of HSPGwas 2.5 times greater in the RA samples
than in the healthy samples (Fig. S1).
In consideration of menopausal status as a factor, independent
sample t testswere performed. Changes inHS andHSPG volume accord-
ing to sample group are illustrated in Fig. 1. There was overwhelming
evidence that menopausal status affected the amount of HSPG in
healthy serum (p value 0.005, confidence interval 95%), while there
was weak evidence that it affected the amount of HS in healthy serum
(p value 0.059, confidence interval 95%). There was insufficient
evidence that menopausal status affected the amount of either HS or
HSPG in RA serum (p values 0.456 and 0.325, respectively, confidence
interval 95%). These conclusions are summarized in Table S1 of the
Supplementary Information.2.2. Significant changes in RA disaccharide profiles
Differences in the disaccharide compositions were observed be-
tween healthy and RA sera. Tables 3 and 4 show the percent composi-
tion of specific disaccharides (Table 1) from free HS fractions and
HSPG fractions, respectively. The values are expressed as themean per-
centage (from all samples in their respective categories) ± SEM.
In both free HS and HSPG fractions, five of the individual disaccha-
rides (ΔUA → GlcNAc6S, ΔUA → GlcNAc, ΔUA2S → GlcNS6S,
ΔUA2S → GlcNS, and ΔUA2S → GlcN6S) were found in significantly
different percentages between healthy and RA samples, irrespective of
menopausal status. The disaccharide ΔUA→ GlcNS6Swas found in sig-
nificantly different percentages between healthy and RA samples for
the free HS fraction only. Four disaccharides (ΔUA2S → GlcNAc6S,
ΔUA2S → GlcNAc, ΔUA → GlcNS, and ΔUA → GlcN6S) were found in
significantly different percentages between healthy and RA samples
for the HSPG fraction only. These significantly different percentages
were identified using independent sample t tests (p values not
shown). Table S2 of the supporting information summarizes these
findings. The proportional differences of the five disaccharides identi-
fied as significantly different in both free HS and HSPG fractions are
illustrated in Fig. 2.
Independent sample t tests indicated that menopausal status was
only a factor for three of the disaccharides in the healthy samples.
There was overwhelming evidence that disaccharide ΔUA → GlcNAc
increased significantly post-menopause in healthy HS (p value .002)
andHSPG (pvalue .000),while therewas strongevidence that disaccha-
ride ΔUA2S → GlcNS6S decreased significantly post-menopause in
healthy HS (p value .004) and HSPG (p value .013). Similarly, there
was clear evidence that disaccharide ΔUA→ GlcNS6S decreased signif-
icantly post-menopause in healthy HSPG (p value .001), but not in
healthy HS.
Fig. 1.Menopausal changes inmedian amounts (μg/ml) of free HS and HSPG. Error bars represent 95% confidence intervals. Only the HSPG in healthy samples indicated significant differ-
ences due to menopausal status.
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3.1. Significant changes in 2-O-sulfation, 6-O-sulfation, N-sulfation and
N-acetylation
Tables 5 and 6 show the percent of disaccharides that are 2-O-
sulfated, 6-O-sulfated, N-sulfated, and N-acetylated (Table 1) in
both free HS and HSPG fractions, respectively. The values are expressed
as the mean percentage (from all samples in their respective catego-
ries) ± SEM. Compared to the healthy samples, RA samples showed
increased 2-O-sulfation and 6-O-sulfation in HS, but decreased 2-O-
sulfation and 6-O-sulfation in HSPG. RA samples also showed increased
N-sulfation in HS, but decreased N-sulfation in HSPG, while these
same samples showed decreased N-acetylation in HS, but increased
N-acetylation in HSPG. Statistically significant differences were
observed between healthy and RA sera with p values b 0.000 in each
case. Figs. 3 and 4 illustrate graphical differences in 2-O-sulfation, 6-O-
sulfation, N-sulfation, and N-acetylation for healthy versus RA samples.3.2. Potential biomarkers identification
The four disaccharides (ΔUA → GlcNAc6S, ΔUA → GlcNS6S,
ΔUA2S → GlcNS6S, and ΔUA2S → GlcN6S) in the HS fraction that
were identified at significantly higher proportions in the RA sample
population were considered as models of potential biomarkers for RA.
The sensitivity and specificity of these potential biomarkers serving as
diagnostic tests were evaluated using the ROC curve (Florkowski,
2008) The area under the corresponding ROC curves (AUC) represents
the performances of these diagnostic tests. A guideline was employed
to rate the performance (Pines et al., 2012) as follows:0.9 ≤ AUC b 1.0 Excellent
0.8 ≤ AUC b 0.9 Good
0.7 ≤ AUC b 0.8 Fair
0.6 ≤ AUC b 0.7 Poor
0.5 ≤ AUC b 0.6 FailTable 2
Banked human sera samples.
Healthy RA
Menopausal status Pre Post Pre Post
Gender Female Female Female Female
Numbers of samples 26 25 25 25
Age 30–46 49–65 32–46 61–81
RF range (IU/ml) 40–2480 42–2690
Anti-CCP range (U/ml) 63–1206 61–1189Fig. 5 shows the ROC curves for the HS-derived disaccharides that
were shown to be present in significantly greater proportions in the
RA samples (ΔUA → GlcNAc6S, ΔUA2S → GlcNS6S, ΔUA → GlcNS6S,
and ΔUA2S → GlcN6S). Disaccharides ΔUA → GlcNAc6S and ΔUA →
GlcNS6S showed AUC values of 0.874 (good) and 0.928 (excellent),
respectively, while the remaining two disaccharides had AUC values
less than 0.80, indicating insufficiency as a diagnostic measure. Fig. 6
shows the ROC curves for the HSPG-derived disaccharides that were
shown to be present in significantly greater proportions in the RAsamples (ΔUA → GlcNAc6S, ΔUA2S → GlcNAc, ΔUA → GlcNAc, and
ΔUA→ GlcNS). In the HSPG fraction, only disaccharide ΔUA→ GlcNAc
(AUC 0.827, good) showed diagnosis predictor potential.
3.3. Implications of heparan sulfate characterization in rheumatoid arthritis
It is believed that heparan sulfate participates in the persistent syno-
vial inflammation characteristic of RA through its involvement in leuko-
cyte transmigration, the essential feature of the inflammatory response
(Parish, 2006). Since early diagnosis of RA is considered important in
decelerating the disease's progression (Aletaha et al., 2010), studies of
heparan sulfate's specific characterizations in RA could provide valuable
information towards development of tools that afford earlier diagnosis.
Herein, we demonstrated the dramatic changes in free HS and HSPG-
derived disaccharide compositions in RA sera compared to those in
healthy sera.
Heparin/heparan sulfate is synthesized on protein cores through a
biosynthetic pathway. The synthesis of HS is a non-template stepwise
process, where various sulfation modifications depend on the activities
of the corresponding enzymes. The NS and NA domains characterized
by N-sulfated and the N-acetylated glucosamines are determined
through the first step by NDST enzymes, as well known from previous
studies by Esko and coworkers (Esko and Lindahl, 2001; Grobe et al.,
2002). The following 2-O and 6-O-sulfation modifications are affected
accordingly, since 2-O-sulfotransferase and 6-O-sulfotransferases tend
to add sulfate groups site specifically in the N-sulfated regions. There-
fore, the variations in the disaccharide profiles can provide important
information regarding the enzymes involved in the HS biosynthetic
pathway along with the other editing enzymes, such as sulfatases and
heparanase.
As illustrated in Fig. 3, RA samples demonstrated overall increases in
6-O-sulfation, 2-O-sulfation, and N-sulfation of HS-derived disaccha-
rides, compared to healthy samples. These variations in sulfation may
be due to the increased expression and/or increased activity of 6-O-
sulfotransferases, resulting in the elevated amount of 6-O-sulfation.
Since the modification of the 6-O position is highly dependent on the
previous N-sulfation and 2-O-sulfation distribution, sulfation might
Table 3
Percent composition of specific disaccharides in free HS from healthy and RA sera. The values are expressed as the mean percentage (from all samples in their respective
categories) ± SEM.
Healthy (%) RA (%)
Disaccharide Pre-menopause Post-menopause Pre-menopause Post-menopause
ΔUA2S → GlcNAc6S 1.49 ± 0.18 1.92 ± 0.19 1.93 ± 0.24 1.71 ± 0.23
ΔUA → GlcNAc6S 7.31 ± 0.39 6.42 ± 0.27 12.41 ± 0.72 10.66 ± 0.74
ΔUA2S → GlcNAc 1.4 ± 0.15 1.2 ± 0.14 1.19 ± 0.19 0.99 ± 0.15
ΔUA → GlcNAc 42.47 ± 1.17 47.46 ± 1.02 31.98 ± 1.82 32.73 ± 1.51
ΔUA2S → GlcNS6S 7.49 ± 0.72 4.75 ± 0.53 9.54 ± 0.49 10.1 ± 1.53
ΔUA → GlcNS6S 9.83 ± 0.6 8.85 ± 0.47 16.75 ± 0.92 18.77 ± 1
ΔUA2S → GlcNS 13.33 ± 0.73 11.99 ± 0.58 10.35 ± 0.57 9.3 ± 0.4
ΔUA → GlcNS 13.67 ± 0.8 14.06 ± 0.61 12.84 ± 0.66 12.81 ± 0.52
ΔUA2S → GlcN6S 0.69 ± 0.08 0.82 ± 0.13 1.1 ± 0.11 1.18 ± 0.1
ΔUA → GlcN6S 1.13 ± 0.14 1.29 ± 0.15 0.95 ± 0.17 0.98 ± 0.2
ΔUA2S → GlcN 0.7 ± 0.07 0.74 ± 0.07 0.78 ± 0.17 0.62 ± 0.11
ΔUA → GlcN 0.48 ± 0.05 0.49 ± 0.05 0.54 ± 0.04 0.47 ± 0.03
57J.K. Sabol et al. / Matrix Biology 40 (2014) 54–61also result in the differential 6-O-sulfatransferase activities. Similarly,
any deficiency in sulfatase enzymes specific to sites other than the 6-
position could also cause an observed increase in those disaccharides
with 6-O-sulfation. Therefore, for women with RA, there is likely to
be either an increase in expression/activity of 6-O-sulfatransferases
and/or deficiencies in sulfatases. Given the specific changes in 6-O-
sulfation in the RA sample population, disaccharides with 6-O-sulfates
may provide valuable information towards the design of future experi-
ments that aim to elucidate disease mechanisms or develop improved
diagnostic tools.
With the exception of the N-acetylated analogs, all RA HS fractions
showed an increase in 2-O-, 6-O- andN-sulfation,while the correspond-
ing HSPG fractions showed a decrease in all three from RA samples
(Tables 4 and 5). Even though the role of N-acetylation is still unclear,
heparan sulfate NA and NS/NA domains might also be crucial. The NA
and NS/NA domains provide a degree of flexibility, which have been
shown to facilitate the interactions between HS and proteins (Mobli
et al., 2008; Casu et al., 2010). Heparan sulfate N-acetylation and 6-O-
sulfation were reported to be involved in the interaction between
natural killer cells and natural cytotoxicity receptors (Bloushtain et al.,
2004). N-acetylation has also been shown to facilitate the binding
with chemokines (Schenauer et al., 2007). For some diseases, such as
mucopolysaccharidosis, changes in the N-acetylation of HS were
reported (Feldhammer et al., 2009; Durand et al., 2010; Holley et al.,
2011). N-acetylation of HS was noticeably different in RA samples,
compared to healthy samples. Fig. 3 graphically demonstrates the
dramatic differences that were observed in the N-acetylated disaccha-
rides when comparing the HS and HSPG fractions. The disaccharide
ΔUA → GlcNAc6S showed dramatically larger mean percentages in
all comparison groups (from HSPG, both pre- and post-menopausal
RA proportionswere 1.4 times larger than healthy). RA samples showed
significantly elevated proportions of the disaccharideΔUA2S→ GlcNAcTable 4
Percent composition of specific disaccharides inHSPG fromhealthy and RA sera. The values are e
Healthy (%)
Disaccharide Pre-menopause Post-men
ΔUA2S → GlcNAc6S 0.95 ± 0.11 1.27 ±
ΔUA → GlcNAc6S 4.24 ± 0.33 4.38 ±
ΔUA2S → GlcNAc 0.51 ± 0.08 0.49 ±
ΔUA → GlcNAc 39.44 ± 0.57 43.92 ±
ΔUA2S → GlcNS6S 10.71 ± 0.6 8.44 ±
ΔUA → GlcNS6S 11.47 ± 0.42 8.78 ±
ΔUA2S → GlcNS 12.58 ± 0.61 11.54 ±
ΔUA → GlcNS 16.33 ± 0.74 17.29 ±
ΔUA2S → GlcN6S 1.72 ± 0.16 1.31 ±
ΔUA → GlcN6S 1.11 ± 0.15 1.47 ±
ΔUA2S → GlcN 0.41 ± 0.06 0.53 ±
ΔUA → GlcN 0.53 ± 0.07 0.59 ±in HSPG (2.0 times greater in pre-menopausal sera and2.3 times greater
in post-menopausal sera), implicating the potential involvement of
2-O-sulfated NA domains in the interaction between HSPG and RA-
related proteins. Disaccharide ΔUA2S → GlcNAc6S was significantly
decreased in HSPG from post-menopausal RA sera. This change in
ΔUA2S→ GlcNAc6Swas specific to the post-menopausal sample popu-
lation, which might suggest an explanation for the severity of RA in the
post-menopausal sera. These findings raise the question of whether the
importance of the N-acetylated regions of HS is underestimated.
The sulfated areas of HS GAGs provide docking sites for protein
ligands such as cytokines, chemokines, and growth factors, thereby
functioning in management of such processes as morphogenesis, tissue
repair, and inflammation (Lindahl and Li, 2009). Heparanase is the
prominent mammalian HS endoglycosidase that cleaves HS side chains
at sites of low sulfation, releasing glycan products that retain the ability
to form biologically active receptor–ligand complexes (Vlodavsky et al.,
2012). Heparanase cleavage of HS in the ECM leads to propagation of
bioactive fragments that facilitate inflammation (Barash et al., 2010).
Indeed, elevated heparanase activity in the synovial fluid of RA patients
has been reported (Li et al., 2008). Upregulation of heparanase in RA is a
likely explanation for our results, which indicated reduced 2-O-
sulfation, 6-O-sulfation, and N-sulfation in HSPG from RA sera, in con-
cert with elevated 2-O-sulfation, 6-O-sulfation (Fig. 4), and N-sulfation
in free HS from RA sera.
3.4. Conclusions
Early diagnosis of RA is known to be advantageous in slowing pro-
gression of the disease (Pruijn et al., 2010), but the diagnosis is still
based on clinical presentation. The current diagnostic tests for RA usual-
ly involve the evaluation of certain antibody levels in blood, such as
rheumatoid factor (RF) and anti-citrullinated protein (APCA). Thesexpressed as themean percentage (from all samples in their respective categories) ± SEM.
RA (%)
opause Pre-menopause Post-menopause
0.14 0.81 ± 0.1 0.7 ± 0.13
0.52 5.97 ± 0.53 6.33 ± 0.46
0.11 1.02 ± 0.16 1.11 ± 0.19
0.74 53.42 ± 2.12 50.03 ± 1.79
0.65 5.48 ± 0.48 5.73 ± 0.34
0.67 9.21 ± 0.54 8.97 ± 0.46
0.54 5.15 ± 0.43 6.04 ± 0.39
0.72 17.34 ± 1.09 19.81 ± 0.86
0.12 0.56 ± 0.06 0.64 ± 0.1
0.16 0.54 ± 0.19 0.18 ± 0.08
0.05 0.4 ± 0.07 0.35 ± 0.05
0.07 0.44 ± 0.08 0.43 ± 0.07
Fig. 2. Five disaccharideswere found in significantly different proportions between healthyandRA samples, in both freeHS andHSPG fractions. Error bars represent95% confidence intervals.
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quate sensitivity and specificity results (Besada et al., 2012). Reliable
predictive biomarker tests are needed (McInnes and Schett, 2011).
Our preliminary data produced ROC curves that suggested that disac-
charides ΔUA → GlcNS6S and ΔUA → GlcNAc6S in serum HS fractions
deserve further attention for their potential as possible RA biomarkers.
In summary, we have applied and optimized the methodology
developed in our lab for the compositional analysis of HS/HSPG-
derived disaccharides from serum samples. We compared the sera of
50 women with rheumatoid arthritis to sera of 51 healthy women.
The comparison groupswere further stratified according tomenopausal
status. Results show dramatic differences in the sulfation and acetyla-
tion patterns between RA and healthy. These changes implicate
the corresponding increased activity of 6-O-sulfotransferases and/or
decreased activity of sulfatases, and decreased activity of 2-O-
sulfotransferase. Thedisaccharide compositions of HS reflect the activity
changes of sulfatases, heparanase, and enzymes involved in the
biosynthetic pathway. Therefore, analysis of the disaccharide profileTable 5
Free HS compositions from healthy and RA sera. The values are expressed as the mean percen
Healthy (%)
Pre-menopause Post-menop
% 2-O-sulfated 15.43 ± 0.78 13.93 ± 0.6
% 6-O-sulfated 18.27 ± 0.76 16.56 ± 0.6
% N-sulfated 44.31 ± 1.03 39.65 ± 0.9
% N-acetylated 52.68 ± 1.06 57 ± 0.8
Table 6
HSPG compositions from healthy and RA sera. The values are expressed as the mean percentag
Healthy (%)
Pre-menopause Post-menop
% 2-O-sulfated 26.88 ± 0.64 23.58 ± 0.7
% 6-O-sulfated 30.2 ± 0.59 25.64 ± 0.8
% N-sulfated 51.08 ± 0.7 46.04 ± 0.9
% N-acetylated 45.14 ± 0.73 50.06 ± 0.8and HS/HSPG concentrations in serum could be promising avenues
for future development of improved RA diagnosis and prognosis meth-
odology. To further investigate the changes of HS-editing enzymes in
RA, enzyme activity studies using the corresponding 2-O- and 6-O-
sulfotransferase, sulfatases and heparanase antibodies are needed, and
are currently in the planning stages.
4. Materials and methods
4.1. Materials
Heparin/heparan sulfate-derived disaccharide standards ΔUA-
GlcNAc, ΔUA2S-GlcNAc, ΔUA-GlcNAc6S, ΔUA2S-GlcNAc6S, ΔUA2S-
GlcNS, ΔUA-GlcNS6S, ΔUA2S-GlcNS6S, ΔUA2S-GlcN6S, ΔUA-GlcN6S,
ΔUA2S-GlcN, ΔUA-GlcN, and ΔUA2S-GlcNCOEt6S were purchased
from V-Labs (Covington, LA). ΔUA-GlcNS was obtained from Iduron
(Manchester, UK). Protease from Streptomyces griseus was purchased
from Sigma-Aldrich (St. Louis, MO). Heparinase I (heparinase, ECtage (from all samples in their respective categories) ± SEM.
RA (%)
ause Pre-menopause Post-menopause
2 24.89 ± 0.77 23.9 ± 1.56
1 42.68 ± 1.49 43.39 ± 1.45
3 49.48 ± 1.58 50.97 ± 1.43
7 47.51 ± 1.49 46.09 ± 1.55
e (from all samples in their respective categories) ± SEM.
RA (%)
ause Pre-menopause Post-menopause
9 13.42 ± 0.99 14.57 ± 0.86
1 22.56 ± 1.02 22.55 ± 0.87
2 37.18 ± 1.77 40.55 ± 1.48
9 61.21 ± 1.8 58.17 ± 1.54
Fig. 3. Amounts of 2-O-sulfation, 6-O-sulfation, N-sulfation, and N-acetylation were
considerably different in RA samples compared to healthy samples. The chart values
reflect mean percentages of total HS/HSPG composition. Error bars represent 95% confi-
dence intervals.
Fig. 5. ROC curves for HS-derived disaccharides ΔUA → GlcNAc6S, ΔUA2S → GlcNS6S,
ΔUA → GlcNS6S, and ΔUA2S → GlcN6S. The areas under the curves are 0.874, 0.759,
0.928, and 0.730, respectively. As indicated in the figure, disaccharides ΔUA→ GlcNAc6S
and ΔUA→ GlcNS6S showed high accuracy (AUC N 0.8) as potential diagnostic measures
of RA.
59J.K. Sabol et al. / Matrix Biology 40 (2014) 54–614.2.2.7), heparinase II (heparitinase II, EC 4.2.2.8), and heparinase III
(heparitinase, EC 4.2.2.8) from Flavobacteriumheparinumwere obtained
from Seikagaku Corporation (East Falmouth, MA). Commercial human
serum was procured from Sigma-Aldrich (St. Louis, MO).
Serum samples from RA women were graciously provided by
Dr. Marcos López-Hoyos from Hospital Universitario Marqués de
Valdecilla. A total of 50 serum samples (Table 2) were analyzed: 25
from premenopausal women (39± 7 years old) and 25 from postmen-
opausal women (71± 10 years old). Sampleswere coded and random-
ized to minimize analytical bias. The daily accuracy and precision of the
purification and analysis method were validated with a commercially
available human serum control (Sigma-Aldrich St Louis,MO)using pub-
lished analytical procedures (Wei et al., 2011, 2013).
4.2. Purification of free HS and HSPG sugar chains from human serum
The originalmethod for freeHS andHSPG purification has been pub-
lished previously (Wei et al., 2013). However, some changes have been
made for this study. Briefly, each of the 50 RA serum samples (70 μL)
was centrifuged at 12,000 ×g for 15 min. The supernatant was diluted
using 0.2 M NaCl and applied to a HiTrap DEAE FF column (GE
Healthcare, Pittsburgh, PA). The column was washed exhaustively
with a low concentration of 0.3 M NaCl. HS and HSPGs were elutedFig. 4. Scatter plot comparison of 6-O-sulfation in serum samples indicates drastic
differences between healthy and RA populations. For each data point, the percentage
identified in the HSPG fraction is plotted against the percentage identified in the free HS
fraction.using a high concentration of 2 M NaCl. The HS was separated from
HSPG using a 50-kDa molecular weight cut-off (MWCO) filter
(Millipore, Billerica, MA). The HSPG fraction was digested by pronase
(0.1mg/mL) overnight at 37 °C using gentle agitation. The HS chains re-
leased from HSPG protein cores were purified using the same DEAE
method. All the DEAE-purified HS fractions were desalted using two
HiTrap desalting columns (GE Healthcare, Pittsburgh, PA) connected
in series and dried in vacuo.
4.3. Digestion and sample clean-up
The HS and HSPG fractions were resuspended in 25 μL of digestion
buffer, containing 20mMNH4OAc (pH 7.5) and 1mMCa(OAc)2. A com-
bination of heparinase enzymes I, II and III (1 mU each) was added to
each HS sample and incubated at 37 °C for 20 h with gentle agitation.
After digestion, each sample was spiked with 2 μL of 20 mM internal
standard I-P (ΔUA2S → GlcNCOEt6S) (Zaia and Costello, 2001; SaadFig. 6. ROC curves for HSPG-derived disaccharides ΔUA→ GlcNAc6S, ΔUA2S → GlcNAc,
ΔUA → GlcNAc, and ΔUA → GlcNS. The areas under the curves are 0.728, 0.704, 0.827,
and 0.603, respectively. As indicated in the figure, disaccharide ΔUA → GlcNAc showed
high accuracy (AUC N 0.8) as a potential diagnostic measure of RA.
60 J.K. Sabol et al. / Matrix Biology 40 (2014) 54–61et al., 2005) and purified using a C18 + carbon SPE TopTip cartridge
(Glygen, Columbia, MD). The cartridge was conditioned 2 times with
50 μL of 0.1% trifluoroacetic acid (TFA) in 80% (v/v) ACN/H2O, followed
by 100 μL of Milli-Q water and 100 μL of 0.5 M NaCl. Each digested
sample was diluted five-fold with 0.5 M NaCl, and then applied to the
cartridge. Subsequently, each cartridge was washed 5 times with
100 μL of Milli-Q water. Heparin/HS-derived disaccharides retained
by the cartridge were eluted with 250 μL of 0.05% TFA in 40% (v/v)
ACN/H2O. All steps were performed in a swinging platform centrifuge
at 2000 rpm for 1 min. The eluted fractions were collected and dried
in vacuo. Finally, samples were redissolved in 20 μL of Milli-Q water
before LC–MS/MS analysis.
4.4. LC–MS/MS analysis
Mass spectra were acquired using a LTQ 2-D linear ion trap mass
spectrometer equipped with an electrospray ionization (ESI) source
and directly coupled to an HPLC system (Thermo Electron, San Jose,
CA). The LC–MS/MS method was described previously (Wei et al.,
2011; Zaia, 2013). Briefly, the purified disaccharide samples were load-
ed onto a Hypercarb column (2.1 mm ID × 150 mm, 5 μm) (Thermo
Fisher Scientific,Waltham,MA) at a flow rate of 200 μL/min. The sample
wasdesaltedwith100% solventA (5mMNH4HCO3/H2O) for 4min, then
eluted in 38% solvent B (5 mM NH4HCO3 in 80% ACN). The MS analysis
was performed in the negative ion mode using a capillary temperature
of 250 °C. The instrument was tuned using disaccharide standards for
optimal performance before sample analysis. For MS/MS experiments,
the precursor ions were selected using an isolation width of 3 Da and
activated using 18–21% normalized collision energy for 100 ms. Data
acquisition and analysis were performed using Xcalibur 2.0 software.
4.5. Statistical analysis
Statistical tests were performed using IBM SPSS Statistics 20. Com-
parisons between groups were performed using independent two-
sample t tests, assuming normal distribution of the larger population.
The evaluation of the potential RA diagnostic variables was performed
using receiver operating characteristic (ROC) curves (Florkowski,
2008). A 95% confidence interval was used with a p value less than
0.05 being considered statistically significant.
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